Repository of Research and Investigative Information

Repository of Research and Investigative Information

Hormozgan University of Medical Sciences

SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

(2018) SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. JOURNAL OF VIRAL HEPATITIS.

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/full_record.do?prod...

Abstract

SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

Item Type: Article
Keywords: SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients
Subjects: WI Digestive System > WI 700-770 Liver. Biliary Tract
Depositing User: هدی فهیم پور
URI: http://eprints.hums.ac.ir/id/eprint/5938

Actions (login required)

View Item View Item